Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From HEC Pharm
Domestic companies have won most of the bids in China's latest government procurement round for 62 drugs, marking an end to the previous dominance of off-patent products from multinationals.
Imminent generic competition to Novartis’ Gilenya blockbuster in the US now seems impossible after a US district court held that the company’s dosage-regimen patent was both valid and infringed by HEC’s ANDA product. The Chinese firm may yet appeal the decision.
After the recent approval of its first all-oral hepatitis C regimen, the China FDA is striving to approve within a year more direct-acting antiviral (DAA) therapies to treat all genotypes of the disease, setting the stage for both multinational and domestic pharma firms to compete in the world’s largest HCV drug market.
A review of biopharma start-up dealmaking and financing from October through December 2016, based on data from Strategic Transactions.
- Generic Drugs
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
- HEC Pharm Co. Ltd.
- Yichang Changjiang Pharmaceutical Co., Ltd.
- Sunshine Lake Pharma Co., Ltd.
- Ruyuan HEC Pharm Co